Burden of proof—Critical flaws in the recommendations from the commission on human medicines Isotretinoin expert working group-Reference-Cited by-同舟云学术

Burden of proof—Critical flaws in the recommendations from the commission on human medicines Isotretinoin expert working group

Published:2023-10-11 Issue:4 Volume:64 Page:579-580
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Tan Eugene¹^ORCID,Kennedy Harriet²³,Rademaker Marius⁴^ORCID

Affiliation:

1. Department of Dermatology Skintel Auckland New Zealand

2. Auckland City Hospital Te Whatu Ora New Zealand

3. Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand

4. Clinical Trials New Zealand Waikato Hospital Campus Hamilton New Zealand

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14169

Reference5 articles.

1. Australasian College of Dermatologists.The ACD position statement on isotretinoin for treatment of acne – updated Aug 2023.2023. Available from:https://www.dermcoll.edu.au/wp‐content/uploads/2023/08/ACD‐Position‐Statement‐Isotretinoin‐August‐2023‐Final‐version.pdf. Accessed Aug 2023.

2. Commission on Human Medicines.Report of the Commission on Human Medicines Isotretinoin Expert Working Group.2023. Available from:https://www.gov.uk/government/publications/report‐of‐the‐commission‐on‐human‐medicines‐isotretinoin‐expert‐working‐group. Accessed Jul 2023.

3. Burdens of proof

4. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survey of Scottish Dermatological Society members on the new Medicines and Healthcare products Regulatory Agency isotretinoin recommendations;Clinical and Experimental Dermatology;2024-06-14

2. Exploring the association between isotretinoin and sexual dysfunction: a comprehensive scoping review;Clinical and Experimental Dermatology;2024-05-04

3. New isotretinoin legislation is based on misinformation;BMJ;2024-02-26